Want to see TSE:OTC full AI Analyst Report?
OTC Stock Chart & Stats
C$0.55
C$0.02(6.45%)
At close: 4:00 PM EST
C$0.55
C$0.02(6.45%)
Day’s Range― - ―
52-Week RangeC$0.35 - C$1.99
Previous CloseN/A
Volume36.17K
Average Volume (3M)77.99K
Market Cap
C$28.89M
Enterprise ValueC$37.05M
Total Cash (Recent Filing)C$436.82K
Total Debt (Recent Filing)C$5.70M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding57,789,104
10 Day Avg. Volume70,232
30 Day Avg. Volume77,988
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)-18.65
Price to Sales (P/S)0.00
P/FCF Ratio-21.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Ophthalmic PipelineThe company’s clear strategic focus on ophthalmic devices and an accommodating IOL provides a durable business model orientation. If regulatory progress converts into a commercial product, the specialized pipeline and domain expertise can create sustainable product-market fit and differentiated revenues over time.
Regulatory / Commercialization PathwayActive progression toward regulatory approval and commercialization is a structural step that, if achieved, transitions the firm from R&D to recurring device sales or licensing. That institutional pathway underpins durable future cash generation potential and makes partnerships or OEM deals more likely over a 2-6 month horizon.
Cash-flow-to-loss AlignmentAlthough cash flow is negative, the close alignment between free cash flow and net loss indicates limited large non‑cash distortions. That predictability improves near-term financial planning and makes funding needs more measurable, aiding durable capital-allocation decisions while the company executes its clinical/commercial milestones.
Bears Say
Weak Balance SheetDeeply negative equity and rising debt materially constrain financial flexibility and increase solvency risk. With a small asset base, the company faces elevated refinancing and covenant risks; lenders and partners may demand stricter terms, making sustained operations dependent on successful capital raises over months.
No Revenue / Growing LossesAbsence of revenue while losses accelerate indicates the firm remains pre-commercial and reliant on external funding. This structural lack of operating income means the company cannot self-fund development; absent clear near-term commercialization, the business model remains high-risk over the 2–6 month horizon.
Sustained Cash BurnConsistent negative operating and free cash flow create persistent funding requirements. With cash burn of multiple millions and limited assets, the company will likely need frequent capital injections; this structural cash deficit elevates dilution and execution risk until positive cash generation begins.
Ocumetics Technology Corp News
OTC FAQ
What was Ocumetics Technology Corp’s price range in the past 12 months?
Ocumetics Technology Corp lowest stock price was C$0.35 and its highest was C$1.99 in the past 12 months.
What is Ocumetics Technology Corp’s market cap?
Ocumetics Technology Corp’s market cap is C$28.89M.
When is Ocumetics Technology Corp’s upcoming earnings report date?
Ocumetics Technology Corp’s upcoming earnings report date is Sep 01, 2026 which is in 41 days.
How were Ocumetics Technology Corp’s earnings last quarter?
Currently, no data Available
Is Ocumetics Technology Corp overvalued?
According to Wall Street analysts Ocumetics Technology Corp’s price is currently Overvalued.
Does Ocumetics Technology Corp pay dividends?
Ocumetics Technology Corp does not currently pay dividends.
What is Ocumetics Technology Corp’s EPS estimate?
Ocumetics Technology Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ocumetics Technology Corp have?
Ocumetics Technology Corp has 57,789,104 shares outstanding.
What happened to Ocumetics Technology Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ocumetics Technology Corp?
Currently, no hedge funds are holding shares in TSE:OTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ocumetics Technology Corp
Ocumetics Technology Corp. is an innovation-driven enterprise specializing in the development and production of diverse optical lenses. One of its key innovations is the Bionic Lens, an expandable intraocular lens crafted to be implanted within the eye's natural lens compartment, offering a solution that eliminates the need for external vision correction. The company maintains its corporate headquarters in Calgary, Canada.
Technical Analysis
Aurora Spine
―
Covalon Technologies
―
Perimeter Medical Imaging AI
―
VentriPoint Diagnostics
―
Conavi Medical
―